NextCell Pharma AB (NXTCL.ST)
SEK 2.42
(-13.57%)
SEK 2.42
(-13.57%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 10.66 Million SEK | 5.45% |
| 2023 | 10.11 Million SEK | 80.96% |
| 2022 | 5.58 Million SEK | 42.86% |
| 2021 | 3.91 Million SEK | 9.74% |
| 2020 | 3.56 Million SEK | 96.71% |
| 2019 | 1.81 Million SEK | 176.49% |
| 2018 | 655.41 Thousand SEK | 26.72% |
| 2017 | 517.2 Thousand SEK | -36.07% |
| 2016 | 809 Thousand SEK | 11523.65% |
| 2015 | 6960.00 SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 1.64 Million SEK | -32.73% |
| 2024 Q1 | 4.24 Million SEK | 50.05% |
| 2024 Q2 | 2.33 Million SEK | -45.03% |
| 2024 Q3 | 2.44 Million SEK | 4.61% |
| 2023 Q3 | 3.03 Million SEK | 44.29% |
| 2023 Q1 | 2.13 Million SEK | 57.21% |
| 2023 FY | 10.11 Million SEK | 80.96% |
| 2023 Q4 | 2.82 Million SEK | -6.91% |
| 2023 Q2 | 2.1 Million SEK | -1.41% |
| 2022 Q3 | 1.61 Million SEK | 27.01% |
| 2022 Q1 | 1.34 Million SEK | 17.09% |
| 2022 Q2 | 1.27 Million SEK | -5.65% |
| 2022 Q4 | 1.35 Million SEK | -15.74% |
| 2022 FY | 5.58 Million SEK | 42.86% |
| 2021 Q3 | 862.82 Thousand SEK | -14.39% |
| 2021 FY | 3.91 Million SEK | 9.74% |
| 2021 Q1 | 1.03 Million SEK | 177.69% |
| 2021 Q2 | 1 Million SEK | -2.8% |
| 2021 Q4 | 1.14 Million SEK | 33.25% |
| 2020 Q4 | 373.38 Thousand SEK | -49.19% |
| 2020 Q3 | 734.92 Thousand SEK | -44.81% |
| 2020 Q2 | 1.33 Million SEK | 17.05% |
| 2020 Q1 | 1.13 Million SEK | 111.07% |
| 2020 FY | 3.56 Million SEK | 96.71% |
| 2019 Q1 | 73.74 Thousand SEK | -42.33% |
| 2019 FY | 1.81 Million SEK | 176.49% |
| 2019 Q3 | 785.94 Thousand SEK | 108.89% |
| 2019 Q4 | 538.97 Thousand SEK | -31.42% |
| 2019 Q2 | 376.25 Thousand SEK | 410.21% |
| 2018 Q4 | 127.86 Thousand SEK | -6.21% |
| 2018 FY | 655.41 Thousand SEK | 26.72% |
| 2018 Q1 | 158.35 Thousand SEK | -20.33% |
| 2018 Q2 | 232.85 Thousand SEK | 47.04% |
| 2018 Q3 | 136.34 Thousand SEK | -41.45% |
| 2017 Q4 | 198.76 Thousand SEK | 0.46% |
| 2017 Q1 | 82.68 Thousand SEK | -69.46% |
| 2017 Q2 | 37.9 Thousand SEK | -54.15% |
| 2017 Q3 | 197.84 Thousand SEK | 421.91% |
| 2017 FY | 517.2 Thousand SEK | -36.07% |
| 2016 Q1 | 89.85 Thousand SEK | 0.0% |
| 2016 FY | 809 Thousand SEK | 11523.65% |
| 2016 Q4 | 270.76 Thousand SEK | -24.48% |
| 2016 Q3 | 358.52 Thousand SEK | 298.99% |
| 2016 Q2 | 89.85 Thousand SEK | -0.0% |
| 2015 FY | 6960.00 SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 81.646% |
| Ziccum AB (publ) | 3.74 Million SEK | -184.62% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 98.269% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 78.876% |
| Mendus AB (publ) | 28.48 Million SEK | 62.563% |
| Genovis AB (publ.) | 158.23 Million SEK | 93.26% |
| Intervacc AB (publ) | 8.01 Million SEK | -33.059% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -143.82% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 93.743% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 75.705% |
| Aptahem AB (publ) | 2.63 Million SEK | -305.402% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -930.406% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -13750.261% |
| Fluicell AB (publ) | 3.33 Million SEK | -219.494% |
| Saniona AB (publ) | 16.84 Million SEK | 36.67% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 34.999% |
| Biovica International AB (publ) | 7.29 Million SEK | -46.292% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -786.509% |
| AcouSort AB (publ) | 10.55 Million SEK | -1.078% |
| Xintela AB (publ) | 78 Thousand SEK | -13572.694% |
| Abliva AB (publ) | 137 Thousand SEK | -7684.453% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 81.485% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -429.528% |
| OncoZenge AB (publ) | 3000.00 SEK | -355390.033% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -6780.452% |
| CombiGene AB (publ) | 5.54 Million SEK | -92.361% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.116% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.379% |
| Corline Biomedical AB | 25.03 Million SEK | 57.392% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -87.825% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -1379.154% |
| I-Tech AB | 120.86 Million SEK | 91.176% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 92.047% |
| Cyxone AB (publ) | 5.14 Million SEK | -107.162% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -51.272% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 5.034% |
| Nanologica AB (publ) | 1.44 Million SEK | -639.065% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -20022.077% |
| BioInvent International AB (publ) | 71.46 Million SEK | 85.076% |
| Alzinova AB (publ) | 270 Thousand SEK | -3849.889% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 69.72% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -628.951% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -277.913% |
| Simris Alg AB (publ) | 4.35 Million SEK | -144.94% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -8103.616% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 95.533% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -46268.265% |